Beijing Jingdu Children's Hospital successfully obtained the international JCI accreditation from July 18, 2020, to July 17, 2023. This accreditation, known as the "gold standard" in global healthcare, signifies that the hospital has achieved world-class standards in medical quality, patient safety, service processes, and more. Every link, from drug management to infection control, and from patient rights protection to medical team collaboration, strictly adheres to international norms, providing international patients with medical (safeguards) on par with developed countries in Europe and America. For example, in drug use, our strict processes certified by JCI ensure the safe and effective procurement, storage, distribution, and administration of every medication, minimizing risks to children from pharmaceutical issues.
The hospital has gathered many renowned domestic and international pediatric experts. Take the Department of Hematology as an example: led by Professor Wu Minyuan, a distinguished expert in pediatric hematology and an "Expert with Special Contribution from the State Council," and Professor Sun Yuan, the hospital director, the expert team is a first-class national team for treating pediatric hematological malignancies.
They possess rich experience in diagnosing and treating complex blood disorders such as leukemia, hemophagocytic syndrome, and bone marrow failure diseases. A research achievement by Beijing Jingdu Children's Hospital on a modified haploid transplantation pretreatment regimen for primary HLH (hemophagocytic lymphohistiocytosis) was published in Pediatric Blood & Cancer, showing a 2-year overall survival rate of 78.4% and a 5-year overall survival rate of 73.7%, bringing new hope to global primary HLH patients. In pediatric cardiac surgery, pioneers in right lateral minithoracotomy for correcting congenital heart deformities in children specialize in right minithoracotomy for various congenital heart diseases and high-difficulty complex cardiac surgeries, helping many international children with congenital heart diseases correct their defects and regain healthy lives.
Jingdu Children's Hospital is equipped with internationally leading medical devices and advanced technologies. For precision diagnosis, it has state-of-the-art gene sequencing equipment that can quickly and accurately detect gene defects in inherited metabolic diseases and rare diseases, providing a basis for personalized treatment.
For instance, in diagnosing hereditary blood diseases, gene testing can identify pathogenic genes within a short time, significantly shortening the diagnostic cycle compared to traditional methods and enabling children to start targeted treatment promptly. In treatment technologies, we actively implement cutting-edge therapies such as cell therapy and targeted therapy.
The Department of Hematology uses advanced technologies like CAR-T cell therapy, CIK cell therapy, and NK cell therapy, offering more cure possibilities for children with blood cancers such as leukemia and lymphoma. Meanwhile, the hospital's 800-square-meter central laboratory provides comprehensive technical support from basic research to clinical application for clinical teams, assisting medical staff in continuously exploring innovative treatment plans, from cell culture to drug development.
In the field of rare diseases, Beijing Jingdu Children's Hospital has accumulated profound diagnostic and therapeutic experience, becoming a beacon of hope for many international families of children with rare diseases. The hospital has a dedicated Rare Disease Multidisciplinary Diagnosis and Treatment (MDT) Center, bringing together experts from departments such as inherited metabolic diseases, neurology, and hematology. Through the MDT model, it formulates personalized diagnostic and treatment plans for rare disease patients.
A European child with Pompe disease, after multiple misdiagnoses locally and deteriorating condition, came to our hospital. The expert team quickly confirmed the diagnosis through gene testing and adopted international advanced enzyme replacement therapy combined with rehabilitation therapy. After months of meticulous treatment, the child's muscle strength significantly improved, and quality of life was greatly enhanced. Additionally, for rare diseases like Fabry disease and Gaucher disease, the hospital has mature diagnostic and treatment protocols, successfully treating many patients from regions such as Asia and Africa.
The hospital also actively participates in international rare disease research projects, maintaining close cooperation with organizations like the International Rare Disease Research Consortium (IRDiRC) to share research results and clinical experiences, contributing to the global development of rare disease diagnosis and treatment.
Beijing Jingdu Children's Hospital has made remarkable achievements in international medical research. In addition to Professor Sun Yuan's breakthrough research in blood disease treatment, the hospital has achieved innovative results in multiple fields. In pediatric neurological disease research, the scientific research team has carried out AI-based early screening studies for childhood autism, epilepsy, and other diseases, with related achievements published in international authoritative journals, providing new directions for global pediatric neurological disease diagnosis and treatment.
In the fields of vaccine development and infectious disease prevention, the hospital collaborates with the World Health Organization (WHO) to participate in clinical trials and efficacy evaluations of multiple pediatric vaccines. The research results help optimize global pediatric vaccination strategies. These advantages in international medical research not only reflect the hospital's scientific research strength but also provide a solid theoretical foundation and innovative ideas for clinical diagnosis and treatment, enabling every international patient who comes here to benefit from cutting-edge medical achievements.
To facilitate medical access for international patients, the hospital has a professional multilingual translation team covering English, French, Spanish, Arabic, and other languages. Whether during outpatient registration, consultation, or inpatient care, international patients can communicate smoothly with medical staff through translators, ensuring accurate understanding of their condition and treatment plans and eliminating medical difficulties caused by language barriers.
The hospital has a teleconsultation center, maintaining long-term cooperation with international top medical institutions such as Massachusetts General Hospital and Boston Children's Hospital in the United States. When facing difficult and complicated cases, international patients can access joint consultations by global top pediatric experts through the teleconsultation platform without long-distance travel, enabling the formulation of optimal treatment plans. This not only saves time and costs but also ensures that children receive international cutting-edge diagnostic and treatment advice in a timely manner.
The international medical inpatient department covers an area of 1,200 square meters, with 16 family wards. Each ward is equipped with independent bathrooms, electric children's beds, fresh air systems, air disinfectors, air purifiers, and other facilities, allowing parents to accompany their children, creating a warm and comfortable environment like home for young patients. During diagnosis and treatment, medical staff pay attention to children's psychological care, adopting child-friendly treatment methods to reduce children's fear of hospitals and make the treatment process smoother.
Over the years, Beijing Jingdu Children's Hospital has accumulated abundant clinical experience, successfully treating a large number of children with complex diseases, including many international patients. There was an acute lymphoblastic leukemia relapse patient from Southeast Asia who (traveled to multiple countries) for treatment with poor results before coming to Jingdu Children's Hospital.
Under the careful treatment of Director Wu Nanhai's team in the Department of Hematology, through precise chemotherapy protocols and meticulous care, the child's condition was effectively controlled, and they were eventually discharged after recovery. There was also an African child with congenital heart disease who, after undergoing high-difficulty heart surgery by Professor Liu Yinglong's team in our pediatric cardiac surgery department, recovered good cardiac function and can now run and play like a normal child. These successful cases not only demonstrate the hospital's medical strength but also build confidence for international patients.
Cost-Effective Treatment:
Compared with many Western countries, medical costs in China are significantly lower. Beijing Jingdu Children's Hospital provides high-quality medical services at costs far below international levels, making it an extremely attractive choice for international patients without compromising treatment quality.
Insurance Coverage:
The hospital accepts China's social medical insurance, commercial medical insurance, and multiple international health insurance plans, providing convenient payment methods and financial security for international patients.
When you worry about your child's health and seek world-class pediatric medical services, Beijing Jingdu Children's Hospital stands as a trustworthy choice with its internationally accredited quality, top expert team, cutting-edge technology and equipment, outstanding advantages in rare disease diagnosis and treatment and international medical research, diversified service system, and rich successful experiences. We look forward to safeguarding your child's health with professionalism and love, allowing every child to regain health and bloom with smiles here.
EN
CN